Tumors

ORLANDO, Fla. — From analytics to treatment and surgery, the role of AI is likely to expand in the field of neurology within the next generation, according to speakers at a plenary session at the American Neurological Association annual meeting.

Precision oncology therapies requiring biomarker testing comprised 43% of all FDA oncology drug approvals between 1998 and 2022, study results published in Cancer Discovery showed.

The addition of stereotactic body radiotherapy to immune checkpoint inhibitors failed to significantly extend survival among individuals with advanced solid tumors, results of the randomized phase 2 CHEERS trial showed.

Steroid use for at least 10 days before surgery was significantly associated with infectious and noninfectious complications, hospital readmissions and mortality in patients undergoing craniotomy for brain tumors, according to research.

A phase 2 trial of trastuzumab deruxtecan met a prespecified target for objective response rate and showed clinically meaningful, durable responses across multiple HER2-expressing advanced solid tumors, according to a company press release.

Among patients with solid tumors, septic shock was associated with a 69.4% 28-day mortality rate, according to a study published in CHEST.

A reduced dosage and updated regimen are now available for the oral small molecule pexidartinib in the treatment of adults with symptomatic tenosynovial giant cell tumor, according to a press release from the drug manufacturer.

The first personalized cellular therapy to use gene replacement for treatment of cancer has shown to be safe in solid tumors, data from a phase 1 study published at Society for Immunotherapy of Cancer Annual Meeting showed.